Kenvue (NYSE:KVUE) Issues Earnings Results

Kenvue (NYSE:KVUE) announced its quarterly earnings data on Thursday. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26, Zacks reports. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. Kenvue updated its FY 2025 guidance to 1.440-1.469 EPS.

Kenvue Stock Performance

KVUE stock traded up $0.30 during midday trading on Friday, reaching $20.10. The stock had a trading volume of 6,644,957 shares, compared to its average volume of 12,328,604. The firm has a fifty day simple moving average of $21.61 and a two-hundred day simple moving average of $21.93. The stock has a market cap of $38.53 billion, a PE ratio of 36.54, a P/E/G ratio of 2.05 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue has a 52-week low of $17.67 and a 52-week high of $24.46.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be paid a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 4.08%. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. UBS Group reduced their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday. JPMorgan Chase & Co. boosted their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $21.00 to $26.00 in a research report on Monday, January 6th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research note on Monday. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus price target of $22.92.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.